Health care stocks were declining late Monday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each falling 1.1%.
The iShares Biotechnology ETF (IBB) dropped 1.3%.
In corporate news, Inogen (INGN) shares rose nearly 6% after the company said Monday it received US Food and Drug Administration clearance for its Simeox 200 airway clearance device, which is designed to help people with chronic respiratory diseases manage bronchial drainage.
Rocket Pharmaceuticals' (RCKT) pipeline development together with its in-house manufacturing capacity are expected to support "strong" long-term growth potential for the company, Wedbush said in a note. Wedbush initiated Rocket with an outperform rating and a $32 price target. Rocket shares added 2.4%.
Marinus Pharmaceuticals (MRNS) shares surged 43% after the company said it signed a deal under which Immedica Pharma will buy all of its issued and outstanding stock for $0.55 a share.
Emergent BioSolutions (EBS) shares jumped 12% after HC Wainwright started coverage of the stock with a buy rating and a $15 price target.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。